With the activation of alternative isoforms of the RAF protein, BRAFV600E, melanoma treated with BRAF inhibitors can become resistant through flexible switching between RAF isoforms capable of ERK pathway signaling, increasing ARAF or CRAF expression. This evidence concerns the gene RAF1 and melanoma.